drugset / Trial / NCT06856837
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Phase 2
Recruiting
140 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, randomized, open-label, multicenter phase II investigating the therapy of Fruquintinib in combination with Tislelizumab in patients with MSS/pMMR metastatic colorectal cancer without liver metastases.
Timeline
- Start
- 2025-10-27
- Primary completion
- 2029-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Fruquintinib | Small molecule | 5 mg | Oral |
| Comparator | Tipiracil | Small molecule | — | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 400 mg | Intravenous |
| Comparator | Trifluridine | Small molecule | — | Oral |